The Canadian Society of Allergy & Clinical Immunology, founded in 1945, published
its first Journal in 1996, as the Canadian Journal of Allergy & Clinical Immunology,
under the Editorship of Dr Gordon Sussman. It was a hard copy journal containing mostly
solicited manuscripts and its circulation was limited primarily to Society members.
In 2004, Allergy, Asthma & Clinical Immunology (AACI) was founded, and was published
by BC Decker from that year until 2009. In 2009, a decision was made to change to
an electronic format and the Journal joined BioMed Central.
It is interesting to note that a number of our most accessed papers were originally
submitted to the hard copy version of the Journal produced by BC Decker (see Table 1).
These articles became generally available because of Open Access with BioMed Central.
This demonstrates the importance of the Open Access system for the dissemination of
medical and scientific information, for at its peak, the hard copy of AACI never had
more than a few hundred subscribers, compared to the 20,000 to 35,000 accesses to
the articles when they transferred to an electronic format.
Table 1
Highly accessed articles (retrieved July 2014)
Title
Year published
Article type
Online accesses
1.
Canadian clinical practice guidelines for acute and chronic rhinosinusitis.
2011
Guideline
34638
2.
Urticaria and infections
2009
Review
27945
3.
Adrenal suppression: A practical guide to the screening and management of under-recognized
complication of inhaled corticosteroid therapy.
2011
Review
24240
4.
Urticaria and angioedema.
2011
Review
22028
5.
International consensus algorithm for the diagnosis, therapy and management of hereditary
angioedema
2010
Guideline
21480
6.
The role of Probiotics in allergic diseases.
2009
Review
20857
7.
Allergic rhinitis.
2011
Review
19923
8.
Hodgkin’s lymphoma presenting with markedly elevated IgE: a case report
2009
Case Report
19033
9.
A practical guide to the monitoring and management of the complications of systemic
corticosteroid therapy
2013
Review
18269
10.
Acquired angioedema
2010
Review
16277
Since joining BioMed Central, under the Editorships of Drs. Warrington, Kim & Watson,
Allergy Asthma & Clinical Immunology has been indexed on PubMed, PubMed Central, Science
Citation Index Expanded, Current Contents, & Scopus. AACI has been tracked by Thompson-Reuters
for an Impact Factor since early 2014, and had an unofficial 2013 impact factor of
1.57. The Scopus Journal Rank (SJR) has increased progressively since 2009 from 0.1
to 0.5-0.6 in 2013 and the Source Normalized Impact per paper (SNIP) has increased
from <0.1 to >0.8.
The number of manuscript publications has also increased progressively since 2010
from 33 in that year to 50 in 2013, the number in 2014 was at 40 as of July 2014.
Regarding the Country of origin of the manuscripts published in the Journal (Table 2),
the majority are from Canada, perhaps not surprisingly, with USA the second highest
contributing country. It is rather striking how few submissions and publications are
from the UK. This area probably needs more attention. Perhaps this reflects the small
number of Allergy & Clinical Immunology training programs in the UK and the fact they
have their own journal, Clinical & Experimental Allergy. The UK is still third on
the list of page visits.
Table 2
Country of origin of publication since 2009
Country
Numbers of publications
Canada
65
USA
27
Germany
11
Japan
8
UK
5
Italy
4
France
4
Others
44
Citations have also increased since joining BioMed Central, from <10 in 2009 to 240
in 2013, an indication of the growing interest in articles published in the Journal.
In terms of citations, it appears that guidelines are more frequently cited than other
manuscripts, although we do not have information on the citation of our Primer on
Allergy & Immunology which was published as a supplement. Articles in that supplement
are among our most highly accessed.
When we compare highly accessed articles all time with those accessed in the last
month (Table 3), there is a significant change in the article types, with a much higher
proportion of manuscripts that are research articles being highly accessed, rather
than reviews or guidelines, which is probably to be expected.
Table 3
Highly accessed articles in last month
Title
Year published
Article type
Online accesses last 30 days
1.
Auto-injector needle length may be inadequate to deliver epinephrine intramuscularly
in women with confirmed food allergy.
2014
Research
3117
2.
Do epinephrine auto-injectors have an unsuitable needle length for young children?
2014
Meeting abstract
3353
3.
A practical guide to the monitoring and management of the complications of systemic
corticosteroid therapy.
2013
Research
2246
4.
Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors
administered into bone.
2014
Research
1516
5.
Adrenal suppression: A practical guide to the screening and management of this under-recognized
complication of inhaled corticosteroid therapy.
2011
Guideline
1551
6.
Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy.
2014
Research
1253
7.
The potential mechanistic link between allergy and obesity development and infant
formula feeding.
2014
Review
1212
8.
Urticaria and angioedema.
2011
Review
1202
9.
Allergic rhinitis.
2011
Review
1102
10.
Peanut Allergy: An Overview.
2008
Review
1047
AACI has also been successful in its publication of supplements. In addition to the
yearly supplement containing abstracts from the Annual Meeting of the Canadian Society
of Allergy & Clinical Immunology, we also publish abstracts from the Allergen NCE
Inc. Annual Meeting, recently held in conjunction with the CSACI Meeting. This extremely
valuable collaboration enhances and expands the basic science interest in the Annual
Meeting and facilitates interactions between basic scientists, clinician scientists
and clinicians.
A second successful contribution by AACI has been in the form of an educational supplement
providing review articles on Allergy & Clinical Immunology topics suitable for Medical
School teaching and the education of non-specialist physicians. The articles in this
supplement have also been among the most accessed publications in AACI. This emphasizes
the strong educational value of the open access system particularly as the cost of
textbooks in Allergy & Immunology increases progressively.
A third successful source of information in AACI is in the form of guidelines for
the treatment and management of allergic and immunologic disease. Some frequently
accessed examples of these guidelines are provided in Table 1.
Reviewing data from Google Analytics, the number of page views per month has increased
progressively to 34,660 in the month of July. Of these, 15,112 were unique visitors,
while new visitors are typically about 20% of all visits. Of these, the majority are
from the United States, followed by Canada, India and the United Kingdom. The number
of new visitors is encouraging with regard to the increasing visibility of the Journal
and interest in its content. Approximately 12,000 sessions originate from Google searches,
compared to 189 from Bing and 143 from Yahoo. Two thousand one hundred and twenty
visits were direct and 668 were from BioMed Central. The latter had the greatest number
of page session, at 5.15, compared to 1.66 from Google and 1.59 from PubMed. Direct
visits, most likely from return visitors, viewed 2.48 pages per session. These data
are interesting in terms of the methods of access to the journal, with a greater number
of visitors from search engines, who view only a limited number of pages, compared
to visitors who come direct to the Journal or through BioMed Central.
In this, our 10th year of publication, we would like to thank the Co-editors of AACI,
the Editorial Board, who have worked hard to make the Journal a success, and the many
reviewers who have contributed their time and expertise.
In addition, we thank the Canadian Society of Allergy & Clinical Immunology, the Executive
and Board and Management team without whose support, both financial and by their contributions
to the Journal; we would not have achieved this success.
Finally, we must thank the many staff at BioMed Central that have contributed to our
success. A special thanks to Lisa Hussey and Holly Young, who have guided the Journal
through the last several years successfully.
When AACI first began publishing in 2004, our goal was to publish high quality research
and review manuscripts, with the aim of eventually achieving indexing in PubMed, Current
Contents etc. Our manuscripts were then by invitation only. Since joining BioMed Central,
we have achieved the aim of indexing, including now Science Citation Index Expanded,
and are awaiting our first official Impact Factor from Thompson Reuters. What we wish
to achieve in the next 10 years is a steady increase in the number and quality of
submissions, so that we can enhance the international reputation of our journal and
Society. This can be achieved by taking advantage of the tremendous advances in our
understanding of allergic and immunologic diseases and the new treatments that have
become available. This knowledge can be widely disseminated by the important medium
of Open Access.
Richard Warrington, Editor-in-Chief, Allergy Asthma & Clinical Immunology
Paul Keith, President, Canadian Society of Allergy & Clinical Immunology